NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other EventsItem 8.01.Other Events.
On July 27, 2017, NewLink Genetics Corporation, a Delaware corporation, or the Company, issued a press release titled "NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802."
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Section9 – Financial Statements and Exhibits
Item 9.01.FinancialStatements and Exhibits.
(d) Exhibits.
|
ExhibitNumber |
Description |
|
99.1 |
Press Release, dated July 27, 2017, entitled “NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802” |
NEWLINK GENETICS CORP ExhibitEX-99.1 2 nlnk-20170727x8kxex991.htm PRESS RELEASE Exhibit Exhibit 99.1FOR IMMEDIATE RELEASENewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802AMES,…To view the full exhibit click here
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.